Mabion SA
WSE:MAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.2
22.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Mabion SA
Total Liabilities
Mabion SA
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mabion SA
WSE:MAB
|
Total Liabilities
zł50m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-3%
|
|
|
R
|
Read Gene SA
WSE:RDG
|
Total Liabilities
zł9.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
2%
|
|
|
G
|
Genomed SA
WSE:GEN
|
Total Liabilities
zł2.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bioton SA
WSE:BIO
|
Total Liabilities
zł195.2m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
U
|
Urteste SA
WSE:URT
|
Total Liabilities
zł1.9m
|
CAGR 3-Years
360%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Total Liabilities
zł179.6m
|
CAGR 3-Years
51%
|
CAGR 5-Years
26%
|
CAGR 10-Years
13%
|
|
Mabion SA
Glance View
Mabion SA is a biotechnology company, which engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 213 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
See Also
What is Mabion SA's Total Liabilities?
Total Liabilities
50m
PLN
Based on the financial report for Sep 30, 2024, Mabion SA's Total Liabilities amounts to 50m PLN.
What is Mabion SA's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
-3%
Over the last year, the Total Liabilities growth was -55%. The average annual Total Liabilities growth rates for Mabion SA have been -34% over the past three years , -15% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
